AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31014283 — intervention group
Group type: COMPARATOR
Intervention: LASIK without MMC application
Number of subjects: 68
Study 28780626 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 150
Study 28780626 — intervention group
Group type: COMPARATOR
Intervention: Control (diagnostic cystoscopy)
Number of subjects: 150
Study 25805217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based body image intervention delivered by undergraduate students
Number of subjects: 62
Study 25805217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 25805217 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (both groups)
Number of subjects: 62
Study 23110355 — intervention group
Group type: EXPERIMENTAL
Intervention: Short integrated study skills programme (SSP)
Number of subjects: 84
Study 23110355 — intervention group
Group type: COMPARATOR
Intervention: Standard academic support (Control)
Number of subjects: 84
Study 21318315 — intervention group
Group type: EXPERIMENTAL
Intervention: Local heat (LH) application for 15 min
Number of subjects: 9
Study 21318315 — intervention group
Group type: COMPARATOR
Intervention: Control period (no heat application)
Number of subjects: 9
Study 19239950 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of EBV LMP-1 gene in cervical metastatic lymph nodes
Number of subjects: 52
Study 19239950 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of EBV LMP-1 gene in nasopharyngeal biopsies
Number of subjects: 52
Study 19239950 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of EBV LMP-1 gene in metastatic lymph nodes of NPC
Number of subjects: 52
Study 19239950 — intervention group
Group type: COMPARATOR
Intervention: Comparison with other head and neck carcinomas and tonsillar specimens
Number of subjects: 52
Study 17971587 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 444
Study 17971587 — intervention group
Group type: COMPARATOR
Intervention: Standard-timing RT at week 9
Number of subjects: 444
Study 17971587 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and RT during induction (up-front RT)
Number of subjects: 444
Study 17971587 — intervention group
Group type: COMPARATOR
Intervention: No RT at all (protocol violation)
Number of subjects: 444
Study 15368110 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium (10 mg daily)
Number of subjects: 0
Study 15368110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11576078 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 0
Study 11576078 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 0
Study 11576078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9519853 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIB (sucrose acetate isobutyrate) ingestion at a dose of 20 mg/kg body weight for 14 days
Number of subjects: 27
Study 9519853 — intervention group
Group type: COMPARATOR
Intervention: Control (gum arabic/water emulsion without SAIB)
Number of subjects: 27
Study 8074599 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-carried prompt card
Number of subjects: 44
Study 8074599 — intervention group
Group type: COMPARATOR
Intervention: Computer-generated prompt
Number of subjects: 44
Study 2801555 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment
Number of subjects: 368
Study 2801555 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy (placebo group)
Number of subjects: 368
Study 2801555 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal left anterior descending coronary artery affected (Streptokinase)
Number of subjects: 368
Study 2801555 — intervention group
Group type: COMPARATOR
Intervention: Proximal left anterior descending coronary artery affected (Anticoagulant therapy)
Number of subjects: 368
Study 822858 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotrophin-releasing hormone (TRH) injection
Number of subjects: 5
Study 822858 — intervention group
Group type: COMPARATOR
Intervention: Nicotinic acid injection
Number of subjects: 5
Study 822858 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 5
Study 31604146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation (beetroot-based high-nitrate supplement)
Number of subjects: 28
Study 31604146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low nitrate 'placebo')
Number of subjects: 28
Study 30728311 — intervention group
Group type: EXPERIMENTAL
Intervention: Submandibular botulinum neurotoxin type A (BoNT‐A)
Number of subjects: 53
Study 30728311 — intervention group
Group type: COMPARATOR
Intervention: Submandibular duct ligation (2‐DL)
Number of subjects: 53
Study 29137842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrozole (1.98 μg)
Number of subjects: 6
Study 29137842 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD-322 (1.98 μg)
Number of subjects: 6
Study 29137842 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (1.98 μg)
Number of subjects: 6
Study 25595351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser photocoagulation
Number of subjects: 80
Study 25595351 — intervention group
Group type: COMPARATOR
Intervention: Liquid paraffin plus antiseptic cream
Number of subjects: 80
Study 23219861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide augmentation
Number of subjects: 32
Study 23219861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21642511 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose PSW treatment (power of 14.5 W, treatment duration of 19 minutes, total energy of 17 kJ)
Number of subjects: 121
Study 21642511 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose PSW treatment (power of 14.5 W, treatment duration of 38 minutes, total energy of 33 kJ)
Number of subjects: 121
Study 21642511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 121
Study 21642511 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 121
Study 18804555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg q.d.)
Number of subjects: 247
Study 18804555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU q.d.)
Number of subjects: 247
Study 18804555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 17303443 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (capacitively coupled, pulsed electrical stimulation device)
Number of subjects: 58
Study 17303443 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 58
Study 15219276 — intervention group
Group type: EXPERIMENTAL
Intervention: (R,R)[123I]-I-QNB with normalization to cerebellum
Number of subjects: 25
Study 15219276 — intervention group
Group type: EXPERIMENTAL
Intervention: (R,R)[123I]-I-QNB with normalization to whole brain
Number of subjects: 25
Study 11236229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination gel (5% benzoyl peroxide and 1% clindamycin)
Number of subjects: 287
Study 11236229 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide
Number of subjects: 287
Study 11236229 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 287
Study 9672013 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cardiac sources of embolism
Number of subjects: 800
Study 9672013 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe carotid obstructions
Number of subjects: 800
Study 9672013 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with carotid obstructive disease
Number of subjects: 800
Study 7973967 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stabilization and fusion
Number of subjects: 113
Study 7973967 — intervention group
Group type: COMPARATOR
Intervention: Laminectomy alone
Number of subjects: 113
Study 7973967 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 113
Study 2511136 — intervention group
Group type: EXPERIMENTAL
Intervention: vasopressin (0.4 to 0.8 unit per min for 12 hr) associated with transdermal nitroglycerin (10 mg in 24 hr)
Number of subjects: 69
Study 2511136 — intervention group
Group type: COMPARATOR
Intervention: vasopressin-placebo
Number of subjects: 69
Study 1015360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfaisomidine administered on an empty stomach
Number of subjects: 8
Study 1015360 — intervention group
Group type: COMPARATOR
Intervention: Sulfaisomidine administered with a standardized breakfast
Number of subjects: 8
Study 31519301 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% cream (CPS)
Number of subjects: 40
Study 31519301 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (PLA)
Number of subjects: 40
Study 29578603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health educator (LHE) intervention with 2 education sessions and 2 telephone follow-up calls on CRC screening plus a CRC brochure
Number of subjects: 304
Study 29578603 — intervention group
Group type: COMPARATOR
Intervention: Attention control with 2 lectures and 2 follow-up calls on nutrition and physical activity plus a CRC brochure
Number of subjects: 304
Study 26658524 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented exercise with mirror therapy (EG)
Number of subjects: 20
Study 24447460 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) delivered by junior professional or para-professional mental health workers
Number of subjects: 440
Study 24447460 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT) delivered by highly trained professional therapists
Number of subjects: 440
Study 24447460 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 440
Study 24447460 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 440
Study 24447460 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) and Cognitive Behaviour Therapy (CBT)
Number of subjects: 440
Study 22475409 — intervention group
Group type: EXPERIMENTAL
Intervention: BP‐NCPAP
Number of subjects: 136
Study 22475409 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 136
Study 21058475 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection therapy with compound Danshen injection at Zusanli (ST 36) and Weishu (BL 21) for 2 weeks
Number of subjects: 102
Study 21058475 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Omeprazole for 2 weeks
Number of subjects: 102
Study 17371590 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 15637764 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Fuzheng Yiliu decoction
Number of subjects: 60
Study 12394376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet for at least two years
Number of subjects: 54
Study 12394376 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 54
Study 10454403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a standard smoking cessation programme with nicotine gum and a behavioural weight control programme including a very low energy diet
Number of subjects: 287
Study 10454403 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with the identical programme but without the diet
Number of subjects: 287
Study 8580269 — intervention group
Group type: EXPERIMENTAL
Intervention: GR122311X 200 mg b.d.
Number of subjects: 1620
Study 8580269 — intervention group
Group type: EXPERIMENTAL
Intervention: GR122311X 400 mg b.d.
Number of subjects: 1620
Study 8580269 — intervention group
Group type: EXPERIMENTAL
Intervention: GR122311X 800 mg b.d.
Number of subjects: 1620
Study 8580269 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine hydrochloride 150 mg b.d.
Number of subjects: 1620
Study 2790864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) 34.7 mM
Number of subjects: 7
Study 2790864 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc citrate 12.0 mM
Number of subjects: 7
Study 2790864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of zinc citrate (14.4 mM) and SLS (34.7 mM)
Number of subjects: 7
Study 1262859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 1
Study 1262859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 1262859 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 1
Study 31556633 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema mindfulness-based cognitive therapy (SMBCT) + treatment as usual (TAU)
Number of subjects: 58
Study 31556633 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive memory therapy (COMET) + treatment as usual (TAU)
Number of subjects: 58
Study 31171755 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (monoclonal antibody against complement C5)
Number of subjects: 0
Study 28147351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileocecal resection with ileocolonic anastomosis
Number of subjects: 0
Study 28147351 — intervention group
Group type: EXPERIMENTAL
Intervention: Strictureplasty
Number of subjects: 0
Study 28147351 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (balloon dilatation and stenting)
Number of subjects: 0
Study 25567087 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful tooth stimulation
Number of subjects: 13
Study 25567087 — intervention group
Group type: COMPARATOR
Intervention: Tooth stimulation below the sensory threshold (control)
Number of subjects: 13
Study 25567087 — intervention group
Group type: COMPARATOR
Intervention: No tooth stimulation (third session)
Number of subjects: 13
Study 23344116 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 knee-ankle-foot orthosis
Number of subjects: 22
Study 23344116 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 knee-ankle-foot orthosis
Number of subjects: 22
Study 23344116 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 3 knee-ankle-foot orthosis
Number of subjects: 22
Study 23344116 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time use of knee-ankle-foot orthoses
Number of subjects: 22
Study 21288340 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention including a depression awareness and physical activity training session for care home staff, plus a whole home physical activation programme with twice weekly physiotherapist-led exercise groups for 12 months.
Number of subjects: 78
Study 21288340 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only a depression awareness training session for care home staff.
Number of subjects: 78
Study 21288340 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 78
Study 18165589 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80
Study 18165589 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 80
Study 18165589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 3 mg
Number of subjects: 80
Study 18165589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17082914 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerated rotating drum reactor (RDR) with lifters
Number of subjects: 0
Study 17082914 — intervention group
Group type: COMPARATOR
Intervention: Aerated rotating drum reactor (RDR) without lifters
Number of subjects: 0
Study 17082914 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil slurry experiments at N = 0.25 s(‐1)
Number of subjects: 0
Study 12646431 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of contrast material plus a 50‐mL saline chaser
Number of subjects: 26
Study 12646431 — intervention group
Group type: COMPARATOR
Intervention: 150 mL of contrast material
Number of subjects: 26
Study 11199427 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue harmonic imaging (THI) sonography
Number of subjects: 25
Study 11199427 — intervention group
Group type: COMPARATOR
Intervention: Conventional sonography
Number of subjects: 25
Study 9350881 — intervention group
Group type: COMPARATOR
Intervention: WHO‐ORS (Group A)
Number of subjects: 238
Study 9350881 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantain flour‐based solution (Group B)
Number of subjects: 238
Study 8411742 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (dose reducing heart rate by 25%)
Number of subjects: 65
Study 8411742 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy (intra‐variceal and extra‐variceal injection of ethanolamine oleate)
Number of subjects: 65
Study 3546687 — intervention group
Group type: EXPERIMENTAL
Intervention: diflunisal
Number of subjects: 33
Study 3546687 — intervention group
Group type: EXPERIMENTAL
Intervention: phenylbutazone
Number of subjects: 33
Study 30460348 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day group (n = 40) with cefozopran (CZOP) given only on the day of surgery
Number of subjects: 82
Study 30460348 — intervention group
Group type: COMPARATOR
Intervention: 5-day group (n = 42) with cefozopran (CZOP) given for 5 consecutive days starting on the day of surgery
Number of subjects: 82
Study 30460348 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day group (n = 40)
Number of subjects: 82
Study 30460348 — intervention group
Group type: COMPARATOR
Intervention: 5-day group (n = 42)
Number of subjects: 82
Study 27072537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 h group (cumulus cells removed at 3 h after insemination)
Number of subjects: 172
Study 27072537 — intervention group
Group type: COMPARATOR
Intervention: 20 h group (cumulus cells removed at 20 h after insemination)
Number of subjects: 172
Study 27072537 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 h group
Number of subjects: 172
Study 27072537 — intervention group
Group type: COMPARATOR
Intervention: 20 h group
Number of subjects: 172
Study 25748876 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct referral to low-dose chest CT (LDCT)
Number of subjects: 493
Study 25748876 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 493
Study 25748876 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access to LDCT
Number of subjects: 493
Study 25748876 — intervention group
Group type: COMPARATOR
Intervention: Fast-track evaluation by chest physician
Number of subjects: 493
Study 23826970 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Plus (ward meetings to discuss results and plan improvements)
Number of subjects: 4236
Study 23826970 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Feedback (ward-specific printed patient survey results including patients' written comments sent to nurses by letter)
Number of subjects: 4236
Study 23826970 — intervention group
Group type: COMPARATOR
Intervention: Control (no active feedback of survey results)
Number of subjects: 4236
Study 20884847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 5 schools)
Number of subjects: 498
Study 20884847 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 5 schools)
Number of subjects: 498
Study 18637080 — intervention group
Group type: EXPERIMENTAL
Intervention: IV butorphanol (1 mg)
Number of subjects: 46
Study 18637080 — intervention group
Group type: COMPARATOR
Intervention: IV ketorolac (30 mg)
Number of subjects: 46
Study 18637080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 18637080 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 46
Study 18637080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 46
Study 16905764 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical medication review by a pharmacist
Number of subjects: 661
Study 16905764 — intervention group
Group type: COMPARATOR
Intervention: Usual general practitioner care
Number of subjects: 661
Study 12969084 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg administered through a nasogastric tube
Number of subjects: 47
Study 12969084 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg administered orally as an intact capsule
Number of subjects: 47
Study 10871933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabrasion
Number of subjects: 15
Study 10871933 — intervention group
Group type: COMPARATOR
Intervention: Carbon dioxide laser resurfacing
Number of subjects: 15
Study 8884304 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day for 7 days, Tinidazole 500 mg bid for 7 days, Clarithromycin 250 mg bid for 7 days (Group A)
Number of subjects: 110
Study 8884304 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg bid for 14 days, Amoxycillin 1000 mg bid for 14 days (Group B)
Number of subjects: 110
Study 8257176 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Few foods' elimination diet
Number of subjects: 78
Study 8257176 — intervention group
Group type: COMPARATOR
Intervention: Provoking foods (in a placebo-controlled double-blind challenge)
Number of subjects: 78
Study 4001769 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 2 G per day for 14 days preceded by 300 mg of levamisole in 2 doses
Number of subjects: 20
Study 4001769 — intervention group
Group type: COMPARATOR
Intervention: Placebo vitamin tablets for 14 days
Number of subjects: 20
Study 31440765 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized regular coaching and exercise
Number of subjects: 362
Study 31440765 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased adherence to the intervention
Number of subjects: 362
Study 29614378 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based internet-delivered cognitive behavior therapy (Internet-CBT)
Number of subjects: 101
Study 29614378 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 101
Study 27609678 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 900
Study 27609678 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 900
Study 25473216 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheet
Number of subjects: 30
Study 25473216 — intervention group
Group type: COMPARATOR
Intervention: Topical silicone gel
Number of subjects: 30